Extranodal site of diffuse large B‐cell lymphoma and the risk of R‐CHOP chemotherapy resistance and early relapse
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Clinical Practice"
DOI: 10.1111/ijcp.13594
Abstract: About 20%‐30% of diffuse large B‐cell lymphoma (DLBCL) patients experience early disease progression despite R‐CHOP chemotherapy treatment. Revised international prognostic index (R‐IPI) score could risk stratify DLBCL patients but does not identify exactly which patient… read more here.
Keywords: chop chemotherapy; early relapse; large cell; diffuse large ... See more keywords
Prognostic significance of CD25 expression in dogs with a noninvasive diagnosis of B-cell lymphoma treated with CHOP chemotherapy.
Sign Up to like & getrecommendations! Published in 2022 at "Veterinary and comparative oncology"
DOI: 10.1111/vco.12857
Abstract: Prior studies have identified high CD25 expression in canine diffuse large B-cell lymphoma as a negative prognostic indicator. The objective of this retrospective study was to evaluate CD25 expression as a prognostic indicator in dogs… read more here.
Keywords: cell lymphoma; cd25; chop chemotherapy; cd25 expression ... See more keywords
Pattern of failure and optimal treatment strategy for primary gastric diffuse large B-cell lymphoma treated with R-CHOP chemotherapy
Sign Up to like & getrecommendations! Published in 2020 at "PLoS ONE"
DOI: 10.1371/journal.pone.0238807
Abstract: Purpose The optimal treatment for primary gastric diffuse large B-cell lymphoma (PG-DLBCL) is still unknown. We evaluated unfavorable prognostic factors and pattern of failure in PG-DLBCL to determine the optimal treatment strategy. Methods Between April… read more here.
Keywords: treated chop; chop chemotherapy; treatment; optimal treatment ... See more keywords
Glycemic Control of Non-Hodgkin Lymphoma (NHL) Non-Diabetes Mellitus (DM) Patient in the First CHOP Chemotherapy
Sign Up to like & getrecommendations! Published in 2021 at "Medico-Legal Update"
DOI: 10.37506/mlu.v21i1.2341
Abstract: Non-Hodgkin’s lymphoma (NHL) chemotherapy is cyclophosphamide, doxorubicin, vincristine, andprednisone (CHOP) have hyperglycemia side effects that affect the success of chemotherapy. Improvedglycemic control decreases morbidity and mortality. Determine the glycemic control changes in non-DMNHL patients before… read more here.
Keywords: chemotherapy; non hodgkin; first chop; chop chemotherapy ... See more keywords